Autologous stem cell transplantation: leukapheresis product has anti-angiogenic effects in vivo correlating with neutrophil-derived VEGFR1
-
Luethy, Anita
Institute of Physiology and Zurich Center for Integrative Human Physiology, University of Zurich, Switzerland
-
Stenner, Frank
Department of Oncology, University Hospital Zurich, Switzerland
-
Lohri, Corinne
Department of Oncology, University Hospital Zurich, Switzerland
-
Muller, Christoph
Institute of Physiology and Zurich Center for Integrative Human Physiology, University of Zurich, Switzerland
-
Samaras, Panagiotis
Department of Oncology, University Hospital Zurich, Switzerland
-
Steiner, Rudolf
Department of Oncology, University Hospital Zurich, Switzerland
-
Broek, Maries Van Den
Department of Oncology, University Hospital Zurich, Switzerland
-
Mischo, Axel
Department of Oncology, University Hospital Zurich, Switzerland
-
Renner, Christoph
Department of Oncology, University Hospital Zurich, Switzerland
-
Knuth, Alexander
Department of Oncology, University Hospital Zurich, Switzerland
-
Rüegg, Curzio
Department of Medicine, Faculty of Science, University of Fribourg, Switzerland
-
Wenger, Roland H.
Institute of Physiology and Zurich Center for Integrative Human Physiology, University of Zurich, Switzerland
-
Zweifel, Martin
Department of Oncology, University Hospital Zurich, Switzerland
Show more…
Published in:
- Anticancer Research. - 2011, vol. 31, no. 10, p. 3115-3124
English
Background: High-dose chemotherapy (HDC) followed by autologous stem cell transplantation (ASCT) is used for the treatment of hemato-oncologic malignancies. In this study, we measured the effect of HDC/ASCT on plasma concentrations of antiangiogenic soluble vascular endothelial growth factor receptor 1 (sVEGFR1) and of leukapheresis products (LP) and patient serum on chick chorioallantoic (CAM) angiogenesis. Materials and Methods: VEGFR1- and CD34-expressing cells of leukapheresis products were analyzed by flow cytometry. Alternatively spliced isoforms of VEGFR1 mRNA were quantified using reverse transcription PCR. Results: Plasma concentrations of sVEGFR1 decreased after HDC, but significantly increased after ASCT. In the CAM assay, sera of patients elicited a proangiogenic effect before and after HDC, but a strong antiangiogenic response after ASCT, comparable to that of bevacizumab at therapeutic concentrations. LP contains high concentrations of sVEGFR1, and high density of VEGFR1+ neutrophilic granulocytes, in which mRNA expression is shifted toward the soluble VEGFR1 isoform. Conclusion: Neutrophil- derived antiangiogenic sVEGFR1 within the LP may contribute to the therapeutic efficacy of ASCT.
-
Faculty
- Faculté des sciences et de médecine
-
Department
- Médecine 3ème année
-
Language
-
-
Classification
-
Biological sciences
- Other electronic version
-
Publisher's version
-
License
-
License undefined
-
Identifiers
-
-
Persistent URL
-
https://folia.unifr.ch/unifr/documents/302469
Statistics
Document views: 44
File downloads: